Hartmann Viaflo (Potassium Chloride, Sodium Chloride, Calcium Chloride Dihydrate, Sodium Lactate)

Hartmann Viaflo is indicated for intravenous fluid and electrolyte replacement in a variety of clinical situations.

• Treatment of hypokalemia (low potassium).
• Management of hyponatremia (low sodium).
• Correction of calcium deficiency or hypocalcemia.
• Support of patients requiring fluid resuscitation after surgery or trauma.
• Use in patients with metabolic acidosis where lactate serves as a buffer.

Adverse reactions to Hartmann Viaflo are generally infrequent, but they can be categorized by frequency and severity.

Common

• Mild infusion site irritation or pain.
• Transient nausea or vomiting.
• Slight increase in serum chloride levels.
• Temporary mild hypernatremia.

Serious

• Severe hyperkalemia leading to cardiac arrhythmia.
• Rapid fluid overload causing pulmonary edema.
• Allergic reaction with rash, urticaria, or anaphylaxis.
• Metabolic alkalosis from excess lactate conversion.

When prescribing Hartmann Viaflo, clinicians should evaluate patient-specific factors and monitor relevant laboratory values.

• Assess baseline electrolyte concentrations, especially potassium, sodium, and calcium.
• Monitor cardiac rhythm in patients at risk for arrhythmias.
• Use caution in renal impairment due to reduced electrolyte excretion.
• Avoid rapid infusion in patients with heart failure or pulmonary edema.
• Adjust dose in patients receiving diuretics or other electrolyte-modifying drugs.
• Consider pregnancy status; safety data are limited.

Hartmann Viaflo may interact with other medications that affect electrolyte balance or fluid status.

Avoid

• Concurrent use of potassium-sparing diuretics or potassium supplements, which can precipitate hyperkalemia.
• High-dose sodium bicarbonate, which may exacerbate hypernatremia.
• Calcium channel blockers combined with large calcium loads, increasing risk of hypercalcemia.

Use with caution

• Loop diuretics, which can cause rapid shifts in potassium and sodium.
• ACE inhibitors or ARBs, which may alter potassium handling.
• Insulin therapy, which drives potassium into cells and may require electrolyte monitoring.